Safety of pulmonary vein isolation in atrial fibrillation patients treated with dabigatran when idarucizumab is available
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2019, Vol 3, Issue 8
Abstract
Patients with atrial fibrillation (AF) are at increased risk of stroke and systemic thromboembolism and prevention of such episodes is ensured by choosing appropriate anticoagulation. In paroxysmal drug‐refractory AF, catheter ablation is the recommended choice of treatment. The decision on whether to stop administration of oral anticoagulant before catheter ablation procedures is often unclear. We present the case of a 67‐year‐old hypertensive woman with a 5‐year history of symptomatic, drug‐refractory paroxysmal AF, who was admitted for pulmonary vein isolation (PVI) and was anticoagulated with dabigatran. After successful transseptal puncture, an intravenous injection of 10 000 units of heparin was administered. Radiofrequency ablation was initiated at the left pulmonary trunk. After the second application of radiofrequency ablation, a drop in arterial blood pressure to 70/50 mmHg was observed. Urgent echocardiography revealed the presence of fluid within the epicardial surface of the left ventricular apex up to 19 mm, behind the right ventricle and right atrium up to 11 mm. Subsequently, all catheters were removed from the left atrium, and 50 mg of protamine sulfate, dopamine, and intravenous fluids were immediately administered. Idarucizumab was urgently delivered to the catheterisation laboratory and was available during patient hospitalisation in the intensive care unit. However, prior to patient discharge, echocardiography revealed only a trace amount of fluid in the pericardium and the use of idarucizumab was not indicated. Interruption of anticoagulation treatment with dabigatran before ablation is not required. Idarucizumab increases the safety of PVI in patients treated with dabigatran. JRCD 2018; 3 (8): 281–283
Authors and Affiliations
Edward Koźluk, Dariusz Rodkiewicz, Agnieszka Piątkowska, Paweł Tomasz Matusik, Grzegorz Opolski
Keywords
Related Articles
- EP ID EP513530
- DOI 10.2041/jrcd.vol3no8.337
- Views 93
- Downloads 0
Rapid progressive idiopathic pulmonary arterial hypertension (RCD code: II-1A.1)
A 48-year-old woman was admitted to our centre with symptoms of right heart failure. Pulmonary arterial hypertension (PAH) was diagnosed. The patient’s general condition deteriorated despiteinitiation of sequential PAH s...
“There is no failure except no longer trying” Elbert Hubbard
The way of time fly is inevitable and the end of 2015 is slowly approaching. Not long ago we were celebrating its onset but now it is time for a farewell. This time of the year is just perfect for a few reflections. Firs...
Third Conference of the Pulmonary Circulation Task Force of the Polish Cardiac Society
Third Conference of the Pulmonary Circulation Task Force of the Polish Cardiac Society was held on 8th‑9th November 2013 in Golebiewski Hotel in Bialystok. The Scientific Committee of the Conference constituted Prof. Mar...
Rhythm disorders and electrocardiographic abnormalities in adult patients with pulmonary arterial hypertension (RCD code: class II)
Cardiac arrhythmias may occur in the course of pulmonary hypertension as a result of structural changes related to pressure overload, myocardial hypertrophy and chamber dilation. Arrhythmias compromise greatly to clinica...
Journal of Rare Cardiovascular Diseases: All that glitters is not gold. Randomized Controlled Trails versus real‑life patients: Challenges of a maturing Journal
Dear Readers,Is time friend or foe? No one has the right answer. With this issue, we are celebrating an important landmark in the Journal’s history. On this occasion, we have looked back at our first two years with a pin...